Joan Lau Joins Rockwell Medical’s Board of Directors

Rockwell Medical Inc. has appointed Joan Lau, Ph.D., to its board of directors. The appointment increases the board’s total to seven members.
 
“We are pleased to welcome Joan to Rockwell Medical’s board of directors,” Board Chairman Robert S. Radie said. “Joan has founded, led, and scaled a number of biotechnology companies throughout her career, possessing a significant amount of business development, operational, and M&A expertise. Additionally, her experience as a public company board member will be valuable to Rockwell Medical as the company continues to grow its customer base and portfolio of products, to serve the needs of dialysis clinics and the patients they serve, and to position Rockwell to achieve its goal of increasing shareholder value.”
 
Dr. Lau has more than 20 years’ experience in executive leadership of R&D focused biopharma as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies. Currently, Dr. Lau is CEO of Spirovant, where she is responsible for the strategic direction and growth of the gene therapy company. Previously, Dr. Lau co-founded and was Managing Partner of Militia Hill Ventures, which focuses on building and growing high quality life sciences companies. Dr. Lau led several biotech companies including Azelon Pharmaceuticals as President and CEO; Locus Pharmaceuticals; and Immunome as COO. Additionally, she served as a director of Renovacor until its acquisition by Rocket Pharmaceuticals and began her career at Merck Research Laboratories.
 
Engaged in the Philadelphia community, Dr. Lau serves on the Boards of Trustees for the University of Pennsylvania, Brandywine Realty Trust, and the Philadelphia Orchestra.

Dr. Lau earned a MBA from the Wharton School of Business and a BSE in bioengineering, both at the University of Pennsylvania, and a Ph.D. in neuroscience from the University of Cincinnati College of Medicine.
 
Rockwell Medical Inc. develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical’s products are vital to vulnerable patients with end-stage kidney disease, and the company is the second largest U.S. supplier of acid and bicarbonate concentrates for dialysis patients